Background and objective: Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack.
Authors:
Prajakta Kashalikar,
Shivani Desai, Avinash Sanap, Madhura Shekatkar, Ramesh Bhonde
Journal: Recent Advances in Inflammation & Allergy Drug Discovery (Formerly as Recent Patents on Inflammation & Allergy Drug Discovery)
Keywords: Immunotherapy; Meta-analysis; Rituximab; Teplizumab; Type1Diabetes
Read Full Review Paper
